Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,425,934

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,425,934 protect, and when does it expire?

Patent 8,425,934 protects BRILINTA and is included in one NDA.

This patent has forty-five patent family members in thirty-four countries.

Summary for Patent: 8,425,934

Title:	Pharmaceutical compositions
Abstract:	The present invention relates to pharmaceutical compositions and, more particularly, to a pharmaceutical composition containing the compound {1S-[1.alpha.,2.alpha.,3.beta.(1S,2R),5.beta.]}-3-(7-{[2-(3,4-difluorop- henyl)cyclopropyl]amino}-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-- 3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.
Inventor(s):	Banks; Simon (Loughborough, GB)
Assignee:	AstraZeneca AB (Sodertalje, SE)
Application Number:	11/841,030
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,425,934
Patent Claim Types: see list of patent claims	Composition; Compound; Formulation; Dosage form;

Drugs Protected by US Patent 8,425,934

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca	BRILINTA	ticagrelor	TABLET;ORAL	022433-002	Sep 3, 2015	AB	RX	Yes	No	⤷ Try it Free	⤷ Try it Free	Y				⤷ Try it Free
Astrazeneca	BRILINTA	ticagrelor	TABLET;ORAL	022433-001	Jul 20, 2011	AB	RX	Yes	Yes	⤷ Try it Free	⤷ Try it Free	Y				⤷ Try it Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,425,934

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	062451	⤷ Try it Free
Australia	2007288541	⤷ Try it Free
Australia	2011205164	⤷ Try it Free
Brazil	PI0715712	⤷ Try it Free
Canada	2659328	⤷ Try it Free
Chile	2007002421	⤷ Try it Free
China	101505754	⤷ Try it Free
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Colorcon

Mallinckrodt

Boehringer Ingelheim

Baxter

AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.